ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 16:10 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 16:10 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
May 09, 2022 16:05 ET | ORIC Pharmaceuticals
Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023 Four...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2022 16:05 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
March 21, 2022 16:00 ET | ORIC Pharmaceuticals
Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call
March 17, 2022 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 16:30 ET | ORIC Pharmaceuticals
ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma ORIC-114 poster presentation to highlight...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference
February 02, 2022 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
January 25, 2022 08:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
January 10, 2022 08:00 ET | ORIC Pharmaceuticals
ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022 Initial Phase 1b data from ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers and ORIC-944...